Repligen (RGEN) -20.3% premarket after the FDA confirms the biotech company must conduct further...


Repligen (RGEN) -20.3% premarket after the FDA confirms the biotech company must conduct further trials before potentially getting approval for its RG1068 synthetic human secretin used to detect pancreatic-duct abnormalities in patients with pancreatitis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs